Efek Inhibitor Proteasom terhadap Histopatologi Arteri Koronaria pada Tikus Model Aterosklerosis
Abstract
Penelitian sebelumnya menunjukkan peranan proteasom pada setiap tahap aterosklerosis yaitu tahap inisiasi, progresi dan komplikasi. Hal ini mendorong penelitian inhibitor proteasom sebagai terapi aterosklerosis dan bortezomib merupakan inhibitor proteasom yang pertama kali dikembangkan. Pada penelitian ini akan dianalisis efek pemberian inhibitor proteasom (bortezomib) terhadap pembentukan lesi aterosklerosis pada arteri koronaria tikus model aterosklerosis tahap progresi. Penelitian ini menggunakan 15 ekor tikus (Rattus novergicus) strain Wistar jantan yang dibagi menjadi 3 kelompok yaitu kelompok kontrol (I), kelompok aterosklerosis (II), dan kelompok aterosklerosis dengan pemberian bortezomib (III). Induksi aterosklerosis dilakukan dengan pemberian vitamin D3 (700.000 IU/kg) secara oral, dan dilanjutkan dengan diet aterogenik (kolesterol 2%, lemak kambing 5%, asam kolat 0,2 % dan diet standar 100%) selama 4 hari. Pemberian bortezomib dosis rendah (50 μg/kgBB) pada hari ke-1 dan ke-3 secara intraperitoneal. Penilaian lesi aterosklerosis dilakukan dengan sistem skoring. Hasil penelitian didapatkan skor lesi tertinggi pada kelompok model aterosklerosis dan adanya penurunan rerata skor lesi aterosklerosis pada kelompok aterosklerosis yang diberi bortezomib (0,70 vs 0,44, p<0,05). Disimpulkan bahwa pemberian bortezomib dapat menghambat pembentukkan lesi aterosklerosis pada tahap progresi.
Keywords
Full Text:
PDFReferences
World Health Organization. Global Status Report On Noncommunicable Diseases 2014. World Health Organization. 2014.
Kementrian Kesehatan Republik Indonesia. Hasil utama Riset Kesehatan Dasar. 2018.
Da̧bek J, Kułach A, Ga̧sior Z. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB): A new potential therapeutic target in atherosclerosis? Pharmacological Reports. 2010;62(5):778–83.
Sargowo D. Patogenesis Aterosklerosis. UB Press. 2015. 82–83
Herrmann J, Lerman LO, Lerman A. On to the Road to Degradation: Atherosclerosis and the Proteasome. Cardiovascular Research. 2010;85(2):291–302.
Murray R. Biokimia harper. 29 ed. Jakarta: Buku Kedokteran EGC; 2014.
Powell SR, Herrmann J, Lerman A, Patterson C, Wang X. The ubiquitin-proteasome system and cardiovascular disease. Progress in Molecular Biology and Translational Science. 2012;109:295–346.
Ismawati, Oenzil F, Yanwirasti, Yerizel E. Changes in expression of proteasome in rats at different stages of atherosclerosis. Anatomy & Cell Biology [Internet]. 2016;49(2):99. Tersedia pada: https://synapse.koreamed.org/DOIx.php?id=10.5115/acb.2016.49.2.99
Wang F, Lerman A, Herrmann J. Dysfunction of the ubiquitin-proteasome system in atherosclerotic cardiovascular disease. American Journal of Cardiovascular Disease. 2015;5(1):83–100.
Eldridge AG, O’Brien T. Therapeutic strategies within the ubiquitin proteasome system. Cell Death & Differentiation. 2010;17(1):4–13.
Wilck N, Ludwig A. Targeting the ubiquitin-proteasome system in atherosclerosis: Status Quo, challenges, and perspectives. Antioxidants and Redox Signaling. 2014;21:2344-63.
Wilck N, Fechner M, Dreger H, Hewing B, Arias A, Meiners S, et al. Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition. Arteriosclerosis, Thrombosis and Vascular Biology. 2012;32(6):1418–26.
Wilck N, Fechner M, Dan C, Stangl V, Stangl K, Ludwig A. The effect of low-dose proteasome inhibition on pre-existing atherosclerosis in LDL receptor-deficient mice. International Journal of Molecular Sciences. 2017;18(4).
Liu Z, Chen T, Niu H, Ren W, Li X, Cui L, et al. The establishment and characteristics of rat model of atherosclerosis induced by hyperuricemia. Stem Cells International. 2016.
Ismawati, Oenzil F, Yanwirasti, Yerizel E. Analisis konsentrasi low density lipoprotein teroksidasi serum pada tahapan aterosklerosis. Jurnal Kedokteran Brawijaya. 2017;29(2017).
Li J, Chen CX, Shen YH. Effects of total glucosides from paeony (paeonia lactiflora Pall) roots on experimental atherosclerosis in rats. Journal of Ethnopharmacology. 2011;135(2):469–75.
Kurniati NF, Nurfatwa M, Anita A. Macrophage activity increases in hypercholesterolemia rat aorta. Majalah Kedokteran Bandung. 2018;50(36):13–20.
Wilck N, Fechner M, Dreger H, Hewing B, Arias A, Meiners S, et al. Attenuation of early atherogenesis in low-density lipoprotein receptor–deficient mice by proteasome inhibition. Arteriosclerosis, Thrombosis and Vascular Biology. Juni 2012;32(6):1418–26.
Van Herck JL, De Meyer GRY, Martinet W, Bult H, Vrints CJ, Herman AG. Proteasome inhibitor bortezomib promotes a rupture-prone plaque phenotype in ApoE-deficient mice. Basic Research in Cardiology. 2010;105(1):39–50.
Stangl K, Stangl V. The ubiquitin-proteasome pathway and endothelial (dys)function. Cardiovascular Research. 2010;85(2):281–90.
Shukla SK, Rafiq K. Proteasome biology and therapeutics in cardiac diseases. Translational Research. 2019;205:64–76.
DOI: https://doi.org/10.24853/jkk.16.2.135-142
Refbacks
- There are currently no refbacks.
 Jurnal Kedokteran dan Kesehatan is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. | |||
 |  |  |  |
| View My Stats | |||